X

Drug Profile

AZD 0292

Alternative Names: AZD-0292

Latest Information Update: 29 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class Antibodies; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Bronchiectasis

Most Recent Events

09 Apr 2024 Phase-I clinical trials in Bronchiectasis (In volunteers) in USA (IV) (NCT06311760)
20 Mar 2024 Preclinical trials in Bronchiectasis in United Kingdom (IV) (Prior to March 2024)
15 Mar 2024 AstraZeneca plans a phase I trial (In volunteers) in the United Kingdom (IV, Infusion) (NCT06311760)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com